LOGIN  |  REGISTER
C4 Therapeutics

Sharecare to report third quarter fiscal 2023 financial results on Thursday, November 9

October 12, 2023 | Last Trade: US$1.43 0.00 0.00

ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- October 12, 2023 – Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced that it will report third quarter fiscal 2023 financial results on Thursday, November 9, 2023, before the market opens. In conjunction, the company will host a conference call to review results at 8:00 a.m. EST on the same day.

Conference Call Details

The conference call can be accessed by dialing (833) 636-1352 for U.S. participants, or (412) 902-4148 for international participants, and asking to be joined into the Sharecare call; or via live audio webcast, available online at https://investors.sharecare.com.

A webcast replay of the call will be available for on-demand listening at the same link and will remain available for approximately 90 days.

About Sharecare

Sharecare is the leading digital health company that helps people – no matter where they are in their health journey – unify and manage all their health in one place. Our comprehensive and data-driven virtual health platform is designed to help people, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. Driven by our philosophy that we are all together better, at Sharecare, we are committed to supporting each individual through the lens of their personal health and making high-quality care more accessible and affordable for everyone. To learn more, visit www.sharecare.com.

Media Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page